Thursday, June 04, 2015 9:17:19 AM
By Brittany Meiling Wednesday, June 3, 2015
Kleanthis Xanthopoulos
http://sdbj.com/news/2015/jun/03/regulus-ceo-apruptly-resigns-chief-science-officer/
Kleanthis Xanthopoulos
Kleanthis Xanthopoulos, who has served more than seven years at the helm of San Diego microRNA drug developer Regulus Therapeutics, unexpectedly resigned as CEO and from the company’s board, according to a statement from the company.
Xanthopoulos is leaving "to pursue investment opportunities in the biotechnology industry," Regulus said.
Chief Scientific Officer Neil Gibson is on his way out, too, leaving former Chief Medical Officer Paul Grint in the CEO spot.
The turnover comes at a pivotal point for Regulus, which is expecting crucial data on the microRNA hepatitis C therapy RG-101 later this year.
Xanthopoulos' surprise exit alarmed investors already wary of RG-101's rollercoaster clinical path so far, sending Regulus' shares down more than 20 percent.
The biotech, formed in 2007 with microRNA assets from Isis Pharmaceuticals and Alnylam Pharmaceuticals, is also working on preclinical candidates for cancer, fibrosis and metabolic disease alongside Big Pharma partners including GlaxoSmithKline, Sanofi and AstraZeneca.
Recent RGLS News
- Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences • PR Newswire (US) • 08/28/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:24:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:16:03 PM
- Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates • PR Newswire (US) • 08/08/2024 08:05:00 PM
- Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference • PR Newswire (US) • 08/06/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2024 08:18:02 PM
- Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences • PR Newswire (US) • 07/09/2024 12:00:00 PM
- This Biotech Wasted No Time Stealing The Premarket Show • AllPennyStocks.com • 06/24/2024 02:00:00 PM
- Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 06/24/2024 11:00:00 AM
- Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes • PR Newswire (US) • 06/04/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:23:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:22:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:22:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:21:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:20:55 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/20/2024 08:11:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:16:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:44:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:38:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:33:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:01 PM
- Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer • PR Newswire (US) • 05/16/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/09/2024 08:54:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:27:12 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM